Aranda Pharma
Develops drug candidates for people with hair loss, acne and brain diseases
Highlights
- New on EvolcAdded 2026-10-28
About Aranda Pharma
Aranda Pharma develops androgen receptor-related therapies. Its ADA-308 drug candidate is being developed as a topical treatment for androgenetic alopecia and acne, while ADA-409 is in its pipeline for brain diseases.
The company is headquartered in Kuopio, Finland, and was founded in 2015. It also has a presence at Terkko Health Hub in Helsinki.
Product: ADA-308 is a topical antiandrogen drug candidate for hair loss and acne; ADA-409 is a candidate for brain diseases.
Jobs at Aranda Pharma
No open positions listed right now.
Leadership
- Mika Käyhkö · CEOSource: company website
- Anu Muona · COOSource: company website
More biotech & pharma companies
Aurealis
Develops bacterial gene therapies for patients with chronic wounds, cancer and inflammatory diseasesNew on EvolcAurlide
Drug discovery services for pharma teams: virtual screening for first hits, hit-to-lead optimization and pharmacokinetics toolsNew on EvolcAvenue Biosciences
Signal peptide engineering with machine learning to raise protein production yields for biologics developersYoung companyRemote-friendlyBioGenium Microsystems
Biomimicking cell culture devices and organ-on-chip systems for researchers in drug development and cancer studiesNew on EvolcBiomendex
Develops synthetic bone graft substitutes for surgeons and veterinary cliniciansNew on EvolcBioNavis
Surface plasmon resonance and QCMD instruments for labs measuring molecular interactions and nanolayersNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Google reCAPTCHA
- LiteSpeed
- jQuery